Summary of Key Information:

Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30, 33 of SEBI Listing Regulations

Audit Opinion:

Clean/Unmodified - Limited Review Report issued by M/s. B S R and Co, Chartered Accountants (FRN - 128510W) with no modifications or qualifications

Key Financial Highlights [₹ in Millions]:

Standalone Results:

Revenue from Operations: ₹1,703.78 (Q1 FY27) vs ₹1,488.26 (Q1 FY26) - 14.5% YoY growth

Total Income: ₹1,765.02 (Q1 FY27) vs ₹1,517.98 (Q1 FY26)

Net Profit: ₹125.63 (Q1 FY27) vs ₹50.14 (Q1 FY26) - 150.6% YoY growth

EPS: Basic ₹1.25, Diluted ₹1.22

Other Equity: Not specified for current quarter

Consolidated Results:

Revenue from Operations: ₹2,817.54 (Q1 FY27) vs ₹2,277.83 (Q1 FY26) - 23.7% YoY growth

Total Income: ₹2,892.13 (Q1 FY27) vs ₹2,343.59 (Q1 FY26)

Net Profit: ₹319.74 (Q1 FY27) vs ₹237.04 (Q1 FY26) - 34.9% YoY growth

EPS: Basic ₹3.19, Diluted ₹3.11

Other Equity: Not specified for current quarter

Geographical Segment Performance (Consolidated):

India: ₹1,553.79 revenue (55.2% of total)

Philippines: ₹906.29 revenue (32.2% of total)

Uzbekistan: ₹321.34 revenue (11.4% of total)

Others: ₹36.12 revenue (1.3% of total)

Corporate Actions:

Committee Reconstitution:

Audit Committee (effective August 17, 2026):

  • Mr. Hemant Sultania, Chairman & Independent Director
  • Ms. Annette Kumlien, Independent Director
  • Mr. Gaurav Sharma, Nominee Director

Stakeholders Relationship Committee (effective August 17, 2026):

  • Mr. Vishal Vijay Gupta, Chairman & Nominee Director
  • Mr. Vikram Vuppala, Managing Director
  • Mr. Om Prakash Manchanda, Independent Director

Internal Restructuring:

Approved transfer of 51% shareholding in Nephrocare Health Services Saudi Arabia Company (NHSSAC) from Nephrocare Health Services International Pte Ltd (NHSI) to Nephro Plus Kidney Services Company (NPKSC)

Consideration: Saudi Riyal 2.24 million

NHSSAC is a joint venture incorporated in Saudi Arabia (January 4, 2023) with zero turnover in FY24, FY25, and FY26

Transaction subject to regulatory approvals in Singapore and Saudi Arabia

Other Significant Information:

IPO Proceeds Utilization (as of June 30, 2026):

Total IPO proceeds: ₹3,251.53 million

Utilized: ₹2,074.83 million (63.8%)

Unutilized: ₹1,176.70 million (36.2%)

Breakdown of utilization:

  • Capital expenditure for new dialysis clinics: ₹127.68 million utilized (9.9% of allocated ₹1,291.06 million)
  • Pre-payment/repayment of borrowings: ₹1,359.99 million utilized (100% of allocated ₹1,359.99 million)
  • General corporate purposes: ₹587.16 million utilized (97.8% of allocated ₹600.48 million)

ESOP Allotment:

Received share application money of ₹11.28 million during Q1 FY26 for ESOP exercises

Allotted 144,320 equity shares on July 14, 2026 against these exercises

Business Combinations:

Entered into seven asset transfer arrangements during Q1 FY27 for aggregate consideration of ₹709.30 million

Initial accounting is provisional pending final identification and measurement of assets acquired

New Subsidiary:

Incorporated NephroPlus Health Services Kazakhstan Limited Liability Partnership on May 26, 2026 as a wholly owned subsidiary in Kazakhstan